A feasibility study to inform the design of a randomised controlled trial to identify the most clinically effective and cost-effective length of Anticoagulation with Low-molecular-weight heparin In the treatment of Cancer-Associated Thrombosis (ALICAT).

BACKGROUND: Venous thromboembolism is common in cancer patients and requires anticoagulation with low-molecular-weight heparin (LMWH). Current data recommend LMWH for anticoagulation as far as 6 months, yet guidelines recommend LMWH beyond 6 months in patients who have ongoing or active cancer. This...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Health Technol Assess
Main Authors: Noble, Simon I, Nelson, Annmarie, Fitzmaurice, David, Bekkers, Marie-Jet, Baillie, Jessica, Sivell, Stephanie, Canham, Joanna, Smith, Joanna D, Casbard, Angela, Cohen, Ander, Cohen, David, Evans, Jessica, Fletcher, Kate, Johnson, Miriam, Maraveyas, Anthony, Prout, Hayley, Hood, Kerenza
Formato: Artigo
Idioma:Inglês
Publicado em: NIHR Journals Library 2015
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4781092/
https://ncbi.nlm.nih.gov/pubmed/26490434
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3310/hta19830
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados